Biogen Idec 8-K 2008
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 4, 2008
Biogen Idec Inc.
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation)
(Registrants Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
TABLE OF CONTENTS
Item 8.01. Other Events.
On March 4, 2008, Biogen Idec Inc. (the Registrant) completed the issuance and sale of $1.0 billion aggregate principal amount of notes, consisting of $450 million of 6.000% Notes due March 1, 2013 (the Notes due 2013) and $550 million of 6.875% Notes due March 1, 2018 (the Notes due 2018, together with the Notes due 2013, the Notes). The Notes were registered on Form S-3 under the Securities Act of 1933 (Registration Statement No. 333-149379). The underwriting agreement and supplemental indenture relating to the issuance and sale of the Notes are attached as exhibits to this filing.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.